tert-Butyl piperazine-1-carboxylate → HCID 58614745, compound
Reaction equation
[Cl:1][C:2]1[CH:3]=[C:4]([CH:8]=[CH:9][C:10]=1[C:11](=[O:26])[NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)[C:5](O)=[O:6].C([N:34]1[CH2:39][CH2:38][NH:37][CH2:36][CH2:35]1)(OC(C)(C)C)=O>>[Cl:1][C:2]1[CH:3]=[C:4]([C:5]([N:34]2[CH2:39][CH2:38][NH:37][CH2:36][CH2:35]2)=[O:6])[CH:8]=[CH:9][C:10]=1[C:11]([NH:12][C:13]1[CH:18]=[CH:17][C:16]([Cl:19])=[C:15]([C:20]2[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=2)[CH:14]=1)=[O:26]Participants
3
Procedure
50 mg 3-chloro-4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to Boc-piperazine via Procedure G. The organic layer was evaporated to dryness and treated with TFA. After 1 h the TFA was removed and the crude was purified on reverse phase HPLC to yield 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(piperazine-1-carbonyl)benzamide. MS (Q1) 455 (M)+.
Workup
- customThe organic layer was evaporated to dryness
- additiontreated with TFA
- customAfter 1 h the TFA was removed
- customthe crude was purified on reverse phase HPLC
Sources & evidence
- ORD record
- ord-be2af4f7cbde4c64b36db6f52a6a061f
- Source dataset
- uspto-grants-2016_03
- Patent number
- US09278961B2
Reaction notes
Loading…